EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Left Ventricular Dysfunction - Pipeline Review, H1 2017

  • ID: 4091124
  • Report
  • February 2017
  • 62 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Amgen Inc
  • Bayer AG
  • Capricor Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Innopharmax Inc
  • Quantum Genomics SA
  • MORE
Left Ventricular Dysfunction - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Left Ventricular Dysfunction - Pipeline Review, H1 2017, provides an overview of the Left Ventricular Dysfunction (Cardiovascular) pipeline landscape.

Left ventricular dysfunction is the most common cause of congestive heart failure. Symptoms include fluid retention, dizziness, fatigue, weakness, irregular heart beat and congested lungs. Risk factors include high blood pressure, diabetes, sleep apnea, alcoholism and coronary artery disease.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Left Ventricular Dysfunction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Left Ventricular Dysfunction (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Left Ventricular Dysfunction (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Left Ventricular Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 2, 7 and 2 respectively.

Left Ventricular Dysfunction (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Left Ventricular Dysfunction (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Left Ventricular Dysfunction (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Left Ventricular Dysfunction (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Left Ventricular Dysfunction (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Left Ventricular Dysfunction (Cardiovascular).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Left Ventricular Dysfunction (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Left Ventricular Dysfunction (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen Inc
  • Bayer AG
  • Capricor Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Innopharmax Inc
  • Quantum Genomics SA
  • MORE
Introduction

Left Ventricular Dysfunction - Overview

Left Ventricular Dysfunction - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Left Ventricular Dysfunction - Companies Involved in Therapeutics Development

Amgen Inc

Bayer AG

Capricor Therapeutics Inc

F. Hoffmann-La Roche Ltd

Innopharmax Inc

Les Laboratoires Servier SAS

Quantum Genomics SA

RedHill Biopharma Ltd

TiGenix NV

Left Ventricular Dysfunction - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Left Ventricular Dysfunction - Drug Profiles

BAY-1142524 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAP-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAP-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

carvedilol CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

carvedilol phosphate CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTX-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omecamtiv mecarbil MR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pirfenidone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QGC-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-38844 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Left Ventricular Dysfunction - Dormant Projects

Left Ventricular Dysfunction - Discontinued Products

Left Ventricular Dysfunction - Product Development Milestones

Featured News & Press Releases

Aug 27, 2013: Amgen to Highlight New Data at Upcoming ESC Congress

Jun 18, 2013: Cytokinetics Announces Presentation Of Results From Phase IIb Clinical Trial Of Omecamtiv Mecarbil At ESC Congress

Feb 19, 2013: RedHill Biopharma Announces Notice Of Allowance From US Patent And Trademark Office For Cardio Drug RHB-101

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Left Ventricular Dysfunction, H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Left Ventricular Dysfunction - Pipeline by Amgen Inc, H1

Left Ventricular Dysfunction - Pipeline by Bayer AG, H1

Left Ventricular Dysfunction - Pipeline by Capricor Therapeutics Inc, H1

Left Ventricular Dysfunction - Pipeline by F. Hoffmann-La Roche Ltd, H1

Left Ventricular Dysfunction - Pipeline by Innopharmax Inc, H1

Left Ventricular Dysfunction - Pipeline by Les Laboratoires Servier SAS, H1

Left Ventricular Dysfunction - Pipeline by Quantum Genomics SA, H1

Left Ventricular Dysfunction - Pipeline by RedHill Biopharma Ltd, H1

Left Ventricular Dysfunction - Pipeline by TiGenix NV, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Left Ventricular Dysfunction - Dormant Projects, H1

Left Ventricular Dysfunction - Discontinued Products, H1

List of Figures:

Number of Products under Development for Left Ventricular Dysfunction, H1

Number of Products under Development by Companies, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 4
  • Amgen Inc
  • Bayer AG
  • Capricor Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Innopharmax Inc
  • Les Laboratoires Servier SAS
  • Quantum Genomics SA
  • RedHill Biopharma Ltd
  • TiGenix NV
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll